CompletedPhase 2NCT01849250
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
Studying Paget disease of the nipple
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ayca Gucalp, M.DMemorial Sloan Kettering Cancer Center
- Intervention
- Docosahexaenoic Acid(drug)
- Enrollment
- 65 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2013 – 2020
Study locations (4)
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Columbia University/Herbert Irving Cancer Center, New York, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01849250 on ClinicalTrials.gov